Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gyeongsang National University Hospital
• Collaborators: Chung-Ang University Hosptial, Chung-Ang University College of Medicine; Dong-A University Hospital
• Treatments: Cisplatin; Erlotinib Hydrochloride; Gemcitabine

Criteria

Inclusion Criteria:

• Age older than 18

• Younger than 75

• ECOG performance status 0 or 1

• Histologically confirmed adenocarcinoma of the pancreas

• Metastatic pancreatic cancer

• No prior chemotherapy for metastatic pancreatic cancer

• A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT)

Exclusion Criteria:

• A patient with no measurable disease

• A patient who received previous palliative chemotherapy for pancreatic cancer

• A patient with locally advanced pancreatic cancer

• A patient who received adjuvant chemotherapy for pancreatic cancer within 1 year

• A patient with previous active or passive immunotherapy

• A pregnant or lactating patient